Alex Zhavoronkov, Angel Investor

Alex Zhavoronkov is the founder and CEO of Insilico Medicine, a generative AI-powered drug discovery company launched in 2014. Under his leadership, Insilico has evolved from algorithms to a fully integrated biotech, raising over $400M, nominating 22 preclinical candidates, and advancing 10 programs into clinical trials, including a Phase IIa success in IPF. He also serves as Chief Business Officer, expanding partnerships and business development in pharma. His career reflects a blend of scientific innovation and entrepreneurial leadership. Beyond Insilico, he has advised Haut.AI on machine vision for skincare and longevity, and served as Chief Longevity Officer at Deep Longevity. He is widely published in AI and biomedicine, with work cited across leading journals and media outlets. As an angel investor, Alex has backed ventures in health and biotech. His recent investments include The Cat Health Company, highlighting his interest in startups applying AI and science to improve health outcomes across both humans and animals.